Inimmune Presents Late-Breaking Phase 1 INI-4001 Results Demonstrating On-Target Immune Activation in Advanced Solid Tumors at SITC 2026

Study demonstrated no dose-limiting toxicities and dose-responsive cytokine production consistent with TLR7/8 engagementResults support continued clinical development of INI-4001 as...

Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)

INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(Newsfile Corp. - November 6, 2026)...

BioScience Health Innovations, Inc. Announces Its Subsidiary Vitalcore Research has Executed Master Distribution Agreement with Rule Imports

Agreement adds $250,000 in research funding and a master distributor relationship to support product development and commercialization across Vitalcore, Best365Labs...

error: Content is protected !!